Back to top
more

Canopy Growth (CGC)

(Delayed Data from NSDQ)

$8.91 USD

8.91
16,404,346

+0.21 (2.41%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $8.91 0.00 (0.00%) 6:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (140 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

Do Options Traders Know Something About Canopy Growth (CGC) Stock We Don't?

Investors need to pay close attention to Canopy Growth (CGC) stock based on the movements in the options market lately.

Canopy Growth Corporation (CGC) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Canopy Growth Corporation (CGC) closed the most recent trading day at $4.79, moving -0.83% from the previous trading session.

ResMed (RMD) Tops Q2 Earnings and Revenue Estimates

ResMed (RMD) delivered earnings and revenue surprises of 3.87% and 0.46%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Canopy Growth Corporation (CGC) Outperforms Broader Market: What You Need to Know

Canopy Growth Corporation (CGC) reachead $4.41 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.

Canopy Growth Corporation (CGC) Stock Drops Despite Market Gains: Important Facts to Note

In the most recent trading session, Canopy Growth Corporation (CGC) closed at $4.56, indicating a -0.87% shift from the previous trading day.

Canopy Growth Corporation (CGC) Gains As Market Dips: What You Should Know

The latest trading day saw Canopy Growth Corporation (CGC) settling at $4.86, representing a +1.46% change from its previous close.

Zacks Market Edge Highlights: Canopy Growth, Tilray Brands, Constellation Brands, Innovative Industrial Properties and Jazz Pharmaceuticals

Canopy Growth, Tilray Brands, Constellation Brands, Innovative Industrial Properties and Jazz Pharmaceuticals are part of the Zacks Market Edge blog.

Tracey Ryniec headshot

Pot Stocks: Values or Traps?

Pot stocks used to be hot but many have plunged over the last 2 years. Are there deals?

Canopy Growth Corporation (CGC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Baxter (BAX) to Report Q3 Earnings: Is a Beat in Store?

Baxter's (BAX) third-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

What's in Store for Canopy Growth (CGC) in Q2 Earnings?

In the second quarter of fiscal 2024, Canopy Growth (CGS) is expected to demonstrate an improved performance in the Canadian cannabis business.

Here's Why Canopy Growth Corporation (CGC) Fell More Than Broader Market

In the closing of the recent trading day, Canopy Growth Corporation (CGC) stood at $0.51, denoting a -1.03% change from the preceding trading day.

What's in Store for Thermo Fisher (TMO) in Q3 Earnings?

Thermo Fisher (TMO) will likely gain from strong Analytical Instrument business performance and latest launches.

Zacks Investment Ideas feature highlights: Canopy Growth, Green Thumb Industries, Tilray Brands and Innovative Industrial Properties

Canopy Growth, Green Thumb Industries, Tilray Brands and Innovative Industrial Properties are part of the Zacks Investment Ideas article.

Abhinab Dasgupta headshot

3 Cannabis Stocks Soaring on HHS' Recommendation to DEA

Canopy Growth (CGC), Tilray (TLRY) and Cronos (CRON) shoot up on news that the DEA is considering recommendations for low-risk reclassification of marijuana.

Andrew Rocco headshot

Time to Get High on Pot Stocks? (3 Catalysts)

When it comes to marijuana, a significant disconnect exists between the US government and the American people. Stock Strategist Andrew Rocco explains why the worst may be over for marijuana investors.

Canopy Growth Corporation (CGC) Reports Q1 Loss, Tops Revenue Estimates

Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of 60% and 16.19%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of 14.04% and 6.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Baxter International (BAX) Lags Q2 Earnings and Revenue Estimates

Baxter (BAX) delivered earnings and revenue surprises of -6.78% and 2.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Canopy Growth (CGC) in Q1 Earnings?

Strong demand for legal cannabis products in the Canadian recreational cannabis market and the launch of new products are expected to have driven Canopy Growth's (CGC) Q1 performance.

Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Canopy Growth Corporation (CGC) closed at $0.39, marking a -0.85% move from the previous day.

Canopy Growth (CGC) Improves Liquidity With Another Selloff

Canopy Growth's (CGC) decision to divest facilities aligns with its organizational transformation plan.

Rockwell Medical (RMTI) Soars 20.0%: Is Further Upside Left in the Stock?

Rockwell Medical (RMTI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Canopy Growth Corporation (CGC) Reports Q4 Loss, Lags Revenue Estimates

Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -91.67% and 10.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Canopy Growth Corporation (CGC) is Poised for a Turnaround After Losing -32.52% in 4 Weeks

Canopy Growth Corporation (CGC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.